RxDoctor Payments Data

Mindy Noll, MD

Family Medicine · Dallastown, PANPI 1265403356

Payments from drug & device makers

$7,870in general payments, 2019–2025

Across 482 payments — averaging $16.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Pfizer$863
  • GSK$759
  • Novo Nordisk$711
  • AstraZeneca$617
  • Lilly USA, LLC$578
  • plus $3K from 48 others

What the payments were for

  • Food & beverage$7,77099%
  • Education$1001%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,870 in reported general payments places this provider in the 90th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$288,472
Medicare patients
400
Services billed
10,313

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban176$154,845
Trelegy ElliptaFluticasone/Umeclidin/Vilanter58$60,253
MounjaroTirzepatide38$46,681
OzempicSemaglutide27$44,293
JardianceEmpagliflozin38$39,561
Nurtec OdtRimegepant Sulfate24$34,110
RybelsusSemaglutide22$33,277
TrulicityDulaglutide29$29,402
FarxigaDapagliflozin Propanediol19$27,465
XareltoRivaroxaban17$25,125
Breo ElliptaFluticasone/Vilanterol33$21,077
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr15$20,674
Tresiba Flextouch U-200Insulin Degludec13$17,725
Synjardy XrEmpagliflozin/Metformin Hcl16$14,569
ArexvyRsvpref3 Antigen/As01e/Pf42$13,386

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Nurtec Odt$863$188,955200 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arexvy, Shingrix$759$128,997209 claims
Novo NordiskOzempic, Rybelsus$711$77,57149 claims
Boehringer IngelheimJardiance, Synjardy Xr, Trijardy Xr, Synjardy$193$76,33677 claims
Lilly USA, LLCMounjaro, Trulicity$578$76,08367 claims
AstraZenecaFarxiga$617$27,46519 claims
Johnson & JohnsonXarelto$309$25,12517 claims
Astellas Pharma US IncMyrbetriq$325$13,21813 claims
AbbVieSynthroid$1,028$2,38162 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Dallastown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →